IRIS International (IRIS) Tops Q3 EPS by 1c; Maintains FY Guidance
More News related to IRIS
- IRIS International to Present at the 21st Annual Piper Jaffray Health Care Conference on December 1, 2009
- IRIS International's Sample Processing Division Enters Veterinary Ova and Parasite Detection Market With New Novel Sample Processing Kit
- IRIS International Names Lawrence J. Blecka, Ph.D., as Vice President, Research and Development of Iris Diagnostics Business Unit
- IRIS Int (IRIS) Posts Q3 Loss of $0.06, Beats by 9c; Guides FY09
- IRIS International (IRIS) Tops Q3 EPS by 1c; Maintains FY Guidance
More News related to Earnings
- Keefe, Bruyette & Woods Downgrades First State Bancorporation (FSNM) to Market Perform
- Keefe, Bruyette & Woods Downgrades R&G Financial (RGFC) to Market Perform
IRIS International, Inc. (NASDAQ: IRIS) reports Q3 EPS of $0.11, 1 cent better than the analyst estimate of $0.10. Revenue for the quarter was $22.2 million, which compares to the estimate of $23.37 million.
IRIS is maintaining guidance for full year 2009, anticipating revenue of $94 - $96 million and earnings of $0.40 - $0.42 per fully diluted share. (Consensus is $94.56M and $0.40, respectively)
The 2009 guidance does not include any revenue relating to NADiA(R)ProsVue(TM), as we have not yet secured regulatory clearance. Research and development expense is expected to be 13% of revenue. The above estimates assume a 27-28% tax rate for the fourth quarter of 2009.
Related Categories
EarningsGuidance
Stocks Mentioned
-0.34Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
